Now I have a thorough understanding of the paper. Let me produce the consolidated review.

## Summary

The paper proposes PharmaVQA, a framework that applies Visual Question Answering (VQA) to molecular graphs. It designs questions about pharmacophore properties (e.g., "how many hydrogen bond donors?"), uses a Bilinear Attention Network (BAN) to attend over the graph while answering these questions, and concatenates the learned pharmacophore features with molecular graph embeddings for downstream tasks. The model is evaluated on 46 datasets spanning property prediction, drug-target interaction, and ligand identification.

## Strengths

- **Extensive benchmarking on 46 datasets across diverse tasks**: The paper evaluates PharmaVQA on Li's 8 classification + 3 regression datasets, the MoleculeACE benchmark (30 regression tasks), two BindingDB DTI datasets, and three ligand targets. This breadth provides substantial evidence of generalizability.

- **Novel application of VQA-style bilinear attention for pharmacophore knowledge injection**: Using BAN to jointly attend over molecular graphs and pharmacophore questions, then using the resulting features as knowledge prompts, is a technically interesting approach. The multi-glimpse mechanism and alignment loss (which forces node-level attention to match known functional group membership) are well-motivated inductive biases.

- **Practical ligand discovery results with competitive hits**: On HPK1, FGFR1, and VIM-1 targets, PharmaVQA's Top-20 predictions include 10, 15, and 16 literature-confirmed ligands respectively, with 6 HPK1 and 4 FGFR1 hits not found by the KPGT baseline, demonstrating practical value.

## Weaknesses

### Major

- **Missing critical baseline: direct use of RDKit-computed pharmacophore counts as features**: The model's core design predicts pharmacophore counts (via a VQA subnetwork) and concatenates them with graph embeddings. The paper never compares against the simple baseline of directly using ground-truth RDKit-computed pharmacophore counts (i.e., removing the VQA subnetwork and feeding deterministic RDKit features directly into the downstream predictor). Without this control, it is impossible to determine whether the complex BAN-based VQA pipeline provides any benefit over a trivial feature addition. All reported gains could come from adding pharmacophore information in any form, not from the VQA framework specifically.

- **Unexplained dual-graph-encoder design**: Section 4.4 states that pharmacophore features \(f\) are concatenated with molecular embeddings from *another* encoder \(Encoder'_g(\mathcal{G})\), distinct from \(Encoder_g(\mathcal{G})\) used for the VQA pathway. The paper provides no justification for why two separate graph encoders are needed, whether they share parameters, or what the computational/training implications are. This is a significant architectural choice left unexamined.

### Minor

- **Overclaimed "retrieval-augmented" framing**: The paper describes itself as a "retrieval-augmented" framework (title, abstract, contributions, conclusion). However, the model does not retrieve information from any external knowledge base or database — it predicts pharmacophore counts from the molecule graph itself via multi-task supervised learning. The term "retrieval" in the standard ML sense implies querying an external corpus, which is not what happens here. While the VQA framing (asking questions and getting answers from the graph) is a reasonable design metaphor, calling it "retrieval-augmented" misleads about the nature of the contribution. The paper would benefit from more precise language (e.g., "multi-task VQA-guided representation learning").

- **Weak interpretability analysis**: The case study (Section 5.6) shows that attention weights highlight question words like "hydrogen", "bond", and "donors" when answering donor-related questions. Since the question itself explicitly contains these words, this is largely circular — the model attending to relevant question tokens is expected behavior of any reasonable attention mechanism. No analysis is performed on which *graph nodes* (atoms) receive attention, no controls (e.g., randomizing question words, comparing on irrelevant pharmacophores) are included, and the claimed demonstration of "ability to mine meaningful information about drug efficacy" is not supported by the presented evidence.

- **Slightly overstated "experimental validation" language**: The abstract states that Top-20 predictions were "experimentally validated as potential ligands previously reported in the literature." In context, this means the predictions match molecules that prior publications experimentally validated as ligands — not that the authors performed experimental validation themselves. The conclusion more accurately says "confirmed by literature reports." The abstract's phrasing could mislead readers into believing wet-lab validation was conducted. This should be corrected.

- **Hyperparameters \(\alpha\) and \(\beta\) unspecified**: The loss function \(L = L_p + \alpha L_{ph} + \beta L_{align}\) has two controllable parameters whose values are never reported, and no sensitivity analysis is provided. Without this information, the results cannot be fully reproduced, and the robustness of the loss weighting is unknown.

### Trivial

None.

## Nice-to-Haves

- An ablation study removing the VQA loss \(L_{ph}\) and alignment loss \(L_{align}\) incrementally to attribute gains to each component.
- Sensitivity analysis of the \(\alpha\) and \(\beta\) hyperparameters.

## Removed Points

These points are flagged to be removed; treat them with caution.

1. **Criticism about missing related work on pharmacophore features (e.g., rule-based fingerprints)**: Per instructions, missing related work criticisms are not allowed as I cannot verify their existence externally.
2. **Claim that "the loss function teaching attention to reproduce RDKit labels is not retrieval"**: While technically the alignment loss uses ground-truth labels, this is knowledge distillation / multi-task learning, not retrieval. This is subsumed by the "overclaimed retrieval-augmented framing" point above and is not a separate weakness.
3. **Criticism about numerical results being in images not parsed**: This is a parser artifact, not an author error. The tables exist in the original submission.
4. **Complaint that the method is "not VQA as typically understood"**: While the method repurposes VQA for structured prediction rather than free-form QA, the paper clearly explains this adaptation. The design is within reasonable scope.
5. **Criticism that the paper claims "real-world studies" in a misleading way**: The abstract says "analyzed in real-world studies" — this refers to analyzing FDA-approved molecule datasets, which is a reasonable use of the term.

## Novel Insights

The most interesting finding not explicitly highlighted by the paper is the *negative* implication of the dual-encoder design: the fact that two separate graph encoders are used suggests the model may be learning redundant representations. If the VQA-guided encoder and the downstream encoder extract different features, the concatenation may be beneficial; if they extract similar features, the computational overhead is wasteful. The paper provides no analysis on this point, but the design choice itself reveals an assumption that pharmacophore-aware and general molecular features are best learned separately — an assumption worth testing.

## Suggestions

1. **Add the RDKit-direct-feature baseline**: Train a variant where ground-truth RDKit pharmacophore counts (or functional-group one-hot vectors) are concatenated directly with the graph encoder output, bypassing the entire VQA subnetwork. If PharmaVQA outperforms this baseline, the VQA framework's contribution is validated. If not, the paper should honestly report this and discuss what the VQA pipeline adds (e.g., end-to-end learning, attention interpretability, multi-task regularization).

2. **Clarify or remove the "retrieval-augmented" language**: Replace "retrieval-augmented" with more precise terminology such as "multi-task VQA-guided" or "knowledge-prompted" to accurately describe what the model does.

3. **Specify the \(\alpha\) and \(\beta\) values** used in experiments and ideally include a sensitivity analysis in an appendix or supplement.

4. **Strengthen the interpretability analysis**: Show attention weights over graph nodes (atoms) rather than just question tokens, or compare attention patterns on molecules where pharmacophores are present vs. absent.

5. **Provide reasoning or ablations for the two-encoder design**: Explain why \(Encoder_g\) and \(Encoder'_g\) are separate, whether they share weights, and whether a single encoder would suffice.

## Score and Decision

The paper has genuine technical contributions — the VQA-guided pharmacophore knowledge injection via BAN, the extensive evaluation, and the practical ligand discovery results are valuable. However, the missing RDKit-direct-feature baseline is a significant experimental gap that prevents clear attribution of the reported gains to the VQA framework itself. Combined with the overstated "retrieval-augmented" framing, the unspecified hyperparameters, and the weak interpretability analysis, the paper in its current form needs substantial revision before acceptance. The core technical idea is interesting and the evaluation is broad, but the experimental design does not yet cleanly support the claimed superiority of the VQA pipeline.

MY FINAL SCORE: <pineapple>5.0</pineapple>
MY FINAL DECISION: <orange>Reject</orange>